Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

US, Europe Sales Boost Gilead Sciences Second Quarter Profit

By Pharmaceutical Processing | July 27, 2011

 

FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. said its profit grew 5
percent in the second quarter as its HIV drug sales grew in Europe and the U.S.

Gilead said its profit
increased to $746.2 million, or 93 cents per share, from $712.1 million, or 79
cents per share, in the year-ago quarter. Excluding special items like
acquisitions, restructuring, and stock-based compensation costs, the company
said it earned $1 per share. Revenue rose 11 percent to $2.14 billion from
$1.93 billion.

Analysts expected a profit of 99 cents per share and $2.1
billion in revenue, according to estimates compiled by FactSet.

The biopharmaceutical company based in Foster City, Calif.,
said its total antiviral drug revenue rose 11 percent to $1.76 billion. Revenue
from the 3-in-1 HIV drug Atripla grew 15 percent to $822 million and sales of
another HIV drug, Truvada, rose 11 percent to $711.3 million. Gilead said the
growth in sales of Atripla and Truvada was driven by greater demand in the U.S. and Europe.
Revenue from the drug Viread, which is used to treat HIV and hepatitis B,
increased 5 percent to $185.7 million.

Gilead said revenue from
its pulmonary arterial hypertension drug Letairis grew 22 percent to $73.6 million,
and sales of its angina drug Ranexa rose 42 percent to $86.1 million. Sales of
other products, like the antifungal drug AmBisome and hepatitis B drug Hepsera,
rose 6 percent to $160.9 million.

Shares of Gilead Sciences fell 48 cents to $42.16 on Tuesday
before the earnings were released. The stock lost another 3 cents in
aftermarket trading.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE